Skip to main navigation Investors COMPANY PROFILE LEADING A NEW PARADIGM IN CARDIOVASCULAR DISEASE MANAGEMENT Amarin Corporation is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve patient health. Our lead commercial product, VASCEPA® (icosapent ethyl), creates a new paradigm in cardiovascular disease management and is positioned to address cardiovascular risk for millions of patients globally. The efficacy and safety profile of VASCEPA, as demonstrated in the landmark REDUCE-IT® cardiovascular outcomes study, has been heralded as one of the most significant breakthroughs in preventative cardiovascular care since statin therapy was introduced nearly three decades ago. VASCEPA is supported by over 100 scientific publications and presentations and recommended for use in appropriate at-risk patients by leading medical societies from around the world, including the United States and Europe. The REDUCE-IT results stand in stark contrast to earlier generation drugs, the clinical studies of which failed to show reduction of persistent cardiovascular risk in their studied populations. LATEST PRESENTATIONS September 2021 Investor Deck View All Investor FAQS Publications NEWS RELEASES Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at the American Heart Association Scientific Sessions 2021 Nov 16, 2021 VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce total ischemic events by 32% in patients with prior PADDUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today r... VIEW ALL NEWS View All EVENTS Nov 22, 2021 Piper Sandler 33rd Annual Virtual Healthcare Conference Nov 16, 2021 at 8:40 AM EST Jefferies 2021 London Healthcare Conference VIEW ALL EVENTS View All Shareholder Tools PRINTED MATERIALS EMAIL ALERTS RSS SEARCH © 2021 Amarin Corporation All rights reserved. Disclaimer Privacy Policy Contact Us Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bridgewater, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN"). AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States. You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders. Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice. Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates. Information on this website may be revised without any prior notice. ACCEPT